Bafilomycin D (CAS 98813-13-9)

Bafilomycin D, a macrolide antibiotic isolated from Streptomyces species, functions as a potent and specific inhibitor of vacuolar-type H+-ATPase (V-ATPase), a critical enzyme involved in proton transport across intracellular and plasma membranes. By binding to the V0 subunit of V-ATPase, Bafilomycin D disrupts the proton gradient required for various cellular processes, such as endocytic and exocytic trafficking, lysosomal acidification, and autophagy. Research has extensively utilized Bafilomycin D as a pharmacological tool to explain the roles of V-ATPase in cellular physiology and pathology. It has been instrumental in investigating lysosomal function, intracellular pH regulation, and the mechanisms underlying diseases such as cancer, neurodegenerative disorders, and infectious diseases. Additionally, Bafilomycin D has been employed in studies exploring the regulation of autophagy, a cellular degradation process crucial for maintaining cellular homeostasis and responding to stress conditions. Its specific inhibition of V-ATPase makes Bafilomycin D a valuable compound in cell biology and biomedical research, offering insights into fundamental cellular processes and providing a basis for the development of novel strategies targeting V-ATPase-related pathways.